Soligenix Announces $7.5M Public Offering with Institutional Investors.

Soligenix, a biopharmaceutical company focused on rare diseases, has priced a $7.5 million public offering with institutional investors for the purchase of 5,555,560 shares of common stock and warrants to purchase up to 5,555,560 shares of common stock at $1.35 per share. The warrants have an exercise price of $1.35 per share and expire immediately.

Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company specializing in rare diseases, has successfully priced its public offering. The company raised approximately $7.5 million by selling 5,555,560 shares of common stock and accompanying warrants to institutional investors at a price of $1.35 per share Soligenix Announces Closing of $7.5 Million Public Offering^[1].

The company's cash runway has been extended to the end of 2026, thanks to this funding. Soligenix plans to use the net proceeds from the offering to support research and development, commercialization activities, working capital, and general corporate purposes Soligenix Announces Closing of $7.5 Million Public Offering^[1].

The public offering included the sale of 5,555,560 shares of common stock and warrants to purchase up to the same number of shares at $1.35 per share. The warrants have an exercise price of $1.35 per share and are exercisable immediately, with an expiration date five years from issuance Soligenix Announces Closing of $7.5 Million Public Offering^[1].

Soligenix's Specialized BioTherapeutics business segment is developing HyBryte™ (SGX301) for cutaneous T-cell lymphoma (CTCL), a rare disease with unmet medical needs. The company's Public Health Solutions business segment includes the development of vaccine candidates for COVID-19 and other infectious diseases Soligenix Announces Pricing of $7.5 Million Public Offering^[2].

The successful pricing of the public offering comes as Soligenix continues to advance its pipeline of rare disease treatments and vaccines. The company's strategic focus on unmet medical needs positions it well to capture opportunities in the biopharmaceutical market.